Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -62.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -62.56% | |||
| Cost of Revenue | -36.94% | -68.46% | |||
| Gross Profit | 35.08% | 68.60% | |||
| SG&A Expenses | 19.42% | 1.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.89% | -37.08% | |||
| Operating Income | -4.72% | 36.73% | |||
| Income Before Tax | 32.11% | 3.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.11% | 3.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.11% | 3.16% | |||
| EBIT | -4.72% | 36.73% | |||
| EBITDA | -6.87% | 37.63% | |||
| EPS Basic | 32.13% | 3.21% | |||
| Normalized Basic EPS | -9.71% | 40.12% | |||
| EPS Diluted | 32.13% | 3.21% | |||
| Normalized Diluted EPS | -9.71% | 40.12% | |||
| Average Basic Shares Outstanding | 0.02% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
